Alzheimer's disease biomarker utilization at first referral enhances differential diagnostic precision with simultaneous exclusion of Creutzfeldt‐Jakob disease

Bibliographic Details
Title: Alzheimer's disease biomarker utilization at first referral enhances differential diagnostic precision with simultaneous exclusion of Creutzfeldt‐Jakob disease
Authors: Zitianyu Wang, Victoria Lewis, Christiane Stehmann, Shiji Varghese, Matteo Senesi, Amelia McGlade, Laura J. Ellett, James D. Doecke, Dhamidhu Eratne, Dennis Velakoulis, Colin L. Masters, Steven J. Collins, Qiao‐Xin Li
Source: Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol 16, Iss 1, Pp n/a-n/a (2024)
Publisher Information: Wiley, 2024.
Publication Year: 2024
Collection: LCC:Neurology. Diseases of the nervous system
LCC:Geriatrics
Subject Terms: Alzheimer's disease, amyloid beta 1‐42, cerebrospinal fluid biomarker, Creutzfeldt‐Jakob disease, differential diagnosis, Elecsys, Neurology. Diseases of the nervous system, RC346-429, Geriatrics, RC952-954.6
More Details: Abstract Most suspected Creutzfeldt‐Jakob disease (CJD) cases are eventually diagnosed with other disorders. We assessed the utility of investigating Alzheimer's disease (AD) biomarkers and neurofilament light (NfL) in patients when CJD is suspected. The study cohort consisted of cerebrospinal fluid (CSF) samples referred for CJD biomarker screening wherein amyloid beta 1‐42 (Aβ1‐42), phosphorylated tau 181 (p‐tau181), and total tau (t‐tau) could be assessed via Elecsys immunoassays (n = 419) and NfL via enzyme‐linked immunosorbent assay (ELISA; n = 161). In the non‐CJD sub cohort (n = 371), 59% (219/371) had A+T– (abnormal Aβ1‐42 only) and 21% (79/371) returned A+T+ (abnormal Aβ1‐42 and p‐tau181). In the 48 CJD subjects, a similar AD biomarker profile distribution was observed. To partially address the prevalence of likely pre‐symptomatic AD, NfL was utilized to assess for neuronal damage. NfL was abnormal in 76% (25/33) of A+T– subjects 40 to 69 years of age, 80% (20/25) of whom had normal t‐tau. This study reinforces AD as an important differential diagnosis of suspected CJD, highlighting that incorporating AD biomarkers and NfL at initial testing is worthwhile.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2352-8729
Relation: https://doaj.org/toc/2352-8729
DOI: 10.1002/dad2.12548
Access URL: https://doaj.org/article/bb39afaf574a49de915fe1b741f84a76
Accession Number: edsdoj.bb39afaf574a49de915fe1b741f84a76
Database: Directory of Open Access Journals
More Details
ISSN:23528729
DOI:10.1002/dad2.12548
Published in:Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Language:English